Skip to main content
SpringerLink
Log in

Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Whether for temporary or long term use, mechanical circulatory support (MCS) has seen increased utilization and interest over the past several years. Even though these devices innately cause thrombocytopenia, co-administration of heparin anticoagulation carries the risk for heparin-induced thrombocytopenia (HIT). This poses challenges for practitioners as very few studies provide guidance for the management of this condition, particularly in this population. This has led to a wide spectrum of treatment protocols within current practice. This review was developed to bring together available literature on the management of HIT in patients with MCS along with practical experience and clinical opinion in order to help guide the management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Warkentin T, Sheppard J, Horsewood P (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96(5):1703–1708

    CAS  PubMed  Google Scholar 

  2. Nand S, Wong W, Yuen B (1997) Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 56:12–16

    Article  CAS  PubMed  Google Scholar 

  3. Warkentin T, Kelton J (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101(5):502–507

    Article  CAS  PubMed  Google Scholar 

  4. Bakchoul T (2016) An update on heparin-induced thrombocytopenia: diagnosis and management. Expert Opin Drug Saf 15(6):787–797

    Article  CAS  PubMed  Google Scholar 

  5. Beiderlinden M, Treschan T, Gorlinger K, Peters J (2007) Argatroban in extracorporeal membrane oxygenation. Artif Organs 31(6):461–465

    Article  CAS  PubMed  Google Scholar 

  6. Izak M, Bussel JB (2014) Management of thrombocytopenia. F1000Prime Rep 6:45

    Article  PubMed  PubMed Central  Google Scholar 

  7. Warkentin TE (2011) Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 27(4):805–823

    Article  PubMed  Google Scholar 

  8. Cuker A, Arepally G, Crowther MA et al (2010) The HIT expert probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8(12):2642–2650

    Article  CAS  PubMed  Google Scholar 

  9. Lillo-Le Louët A BP, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, Lasne D (2004) Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2:1882–1888

    Article  PubMed  Google Scholar 

  10. Lo G, Juhl D, Warkentin T, Sigouin C, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765

    Article  CAS  PubMed  Google Scholar 

  11. Lillo-Le Louet A, Boutouyrie P, AlheneGelas M, LeBeller C, Gautier I et al (2004) Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2:1882–1888

    Article  CAS  PubMed  Google Scholar 

  12. Warkentin T (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535–555

    Article  CAS  PubMed  Google Scholar 

  13. Chaturvedi S, Kohli R, McCrae K (2015) Over-testing for heparin induced thrombocytopenia in hospitalized patients. J Thromb Thrombolysis 40(1):12–6

  14. Lubenow N, Eichler P, Lietz T, Greinacher A (2005) Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT- 3. J Thromb Haemost 3:2428–2436

    Article  CAS  PubMed  Google Scholar 

  15. Selleng S, Malowsky B, Itterman T et al (2010) Incidence and clinical relevance of antiplatelet factor 4/heparin antibodies before cardiac surgery. Am J Heart 160:362–369

    Article  CAS  Google Scholar 

  16. Bauer T, Arepally G, Konkle B et al (1997) Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242–1246

    Article  CAS  PubMed  Google Scholar 

  17. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, for the HIT Investigators Group (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99:73–80

    Article  CAS  PubMed  Google Scholar 

  18. Greinacher A, Janssens U, Berg G, Böck M, Kwasny H, Kemkes-Matthes B, Eichler P, Völpel H, Pötzsch B, Luz M, for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100:587–593

    Article  CAS  PubMed  Google Scholar 

  19. Lubenow N, Eichler P, Lietz T, Greinacher A, the HIT investigator group (2005) Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3:2428–2436

    Article  CAS  PubMed  Google Scholar 

  20. Warkentin T, Greinacher A (2004) Heparin-Induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):311 S–337 S

    Article  CAS  Google Scholar 

  21. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis. 9th edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e495S–e530S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Slaughter M, Sobieski M 2nd, Graham J (2011) Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs 34:461–468

    Article  CAS  PubMed  Google Scholar 

  23. John R, Panch S, Hrabe J (2009) Activation of endothelial and coagulation systems in left ventricular assist device recipients. An Thorac Surg 88:1171–1179

    Article  Google Scholar 

  24. Kaplon R, Gillinov A, Smedira N (1999) Vitamin K reduces bleeding in left ventricular assist device recipients. J Heart Lung Transplant 18:346–350

    Article  CAS  PubMed  Google Scholar 

  25. Rossi M SG, Jiritano F (2012) What is the optimal anticoagulation in patients with a left ventricular assist device? Interat Cardovasc Thorac Surg 15(4):733–740

    Article  Google Scholar 

  26. Russel S SM, Pagani F, Moore S, Idrissi K, Klodell C (2006) HeartMate II LVAS: Patient management guidelines

  27. Slaughter M, Naka Y, John R (2010) Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant 29:616–624

    Article  PubMed  Google Scholar 

  28. Boyle A, Russell S, Teuteberg J (2009) Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 28:881–887

    Article  PubMed  Google Scholar 

  29. Pagani F, Miller L, Russell S (2009) Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 54:312–321

    Article  PubMed  Google Scholar 

  30. Fuster V, Rydén LE, Asinger RW et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society of pacing and electrophysiology. Circulation 104:2118–2150

    CAS  PubMed  Google Scholar 

  31. Webb DP, Warhoover MT, Eagle SS, Greelish JP, Zhao DX, Byrne JG (2008) Argatroban in short-term percutaneous ventricular assist subsequent to heparin-induced thrombocytopenia. J Extra Corpor Technol 40(2):130–134

    PubMed  PubMed Central  Google Scholar 

  32. Shigemitsu O, Hadama T, Takasaki H, Mori Y, Kimura T, Miyamoto S et al (1994) Biocompatibility of a heparin-bonded membrane oxygenator (Carmeda MAXIMA) during the first 90 min of cardiopulmonary bypass: clinical comparison with the conventional system. Artif Organs 18:936–941

    CAS  PubMed  Google Scholar 

  33. Sundaram S, Courtney JM, Taggart DP, Tweddel AC, Martin W, McQuiston AM et al (1994) Biocompatibility of cardiopulmonary bypass: influence on blood compatibility of device type, mode of blood flow and duration of application. Int J Artif Organs 17:118–128

    CAS  PubMed  Google Scholar 

  34. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH (1996) Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 93:2014–2018

    Article  CAS  PubMed  Google Scholar 

  35. Brister SJ, Ofosu FA, Buchanan MR (1993) Thrombin generation during cardiacsurgery: heparin the ideal anticoagulant. Thromb Hemost 70:259–262

    CAS  Google Scholar 

  36. Khuri SD, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA et al (1995) Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 60:1008–1014

    Article  CAS  PubMed  Google Scholar 

  37. Vander Kamp KW, van Deveren W (1993) Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. Int J Artif Organs 16:836–842

    CAS  Google Scholar 

  38. Benken S, Tillman N, Dajani S, Shah A, Thomas T (2014) A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients. J Cardiothorac Surg 9:55

    Article  PubMed  PubMed Central  Google Scholar 

  39. Gellatly R, Leet A, Brown K (2013) Fondaparinux: an effective bridging strategy in heparin-induced thrombocytopenia and mechanical circulatory support. J Heart Lung Transplant. doi:10.1016/j.healun.2013.07.015

    PubMed  Google Scholar 

  40. Warkentin T, Pai M, Sheppard J, Schulman S, Spyropoulos A, Eikelboom J (2011) Fondaparinux treatment of acute heparin induced thrombocytopenia confirmed by the serotonin-releaseassay: a 30-month, 16-patient case series. J Thromb Haemost 9(12):2389–2396

    Article  CAS  PubMed  Google Scholar 

  41. Shantsila E, Lip G, Chong B (2009) Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest 135(6):1651–1664

    Article  CAS  PubMed  Google Scholar 

  42. Bates ER (2004) Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2:153–156

    Article  CAS  PubMed  Google Scholar 

  43. Koster A, Rosendahl U, von Hodenberg E, Ennker J (2010) Management of protamine allergy with bivalirudin during coronary artery revascularization. Ann Thorac Surg 90:276–277

    Article  PubMed  Google Scholar 

  44. Pappalardo F, Franco A, Crescenzi G, Poli A, Zangrillo A, Koster A (2007) Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. Perfusion 22:67–69

    Article  CAS  PubMed  Google Scholar 

  45. Anand S, Viles-Gonzalez J, Mahboobi S, Heerdt P (2011) Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anaesth 58:296–311

    Article  PubMed  Google Scholar 

  46. Skrupky L, Smith J, Deal E (2010) Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy 30(12):1229–1238

    Article  CAS  PubMed  Google Scholar 

  47. Bain J, Meyer A (2013) Comparison of bivalirudinto lepirudin and argatroban in patients with heparin induced thrombocytopenia. JHPR 4:1

    Google Scholar 

  48. Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW (2009) Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 43:19–27

    Article  CAS  PubMed  Google Scholar 

  49. Tsu LV, Dager WE (2011) Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother 45(10):1185–1192

    Article  CAS  PubMed  Google Scholar 

  50. Guzzi LM, McCollum DA, Hursting MJ (2006) Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169–176

    Article  CAS  PubMed  Google Scholar 

  51. Dang CH DV, Nappi JM (2006) Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 26(4):461–468

    Article  CAS  PubMed  Google Scholar 

  52. Runyan CL CK, Riker RR (2011) Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy 31(9):850–856

    Article  CAS  PubMed  Google Scholar 

  53. Koster A, Spiess B, Chew DP et al (2004) Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93:356–359

    Article  CAS  PubMed  Google Scholar 

  54. Veal JJ, McCarthy HM, Palmer G, Dyke CM (2005) Use of bivalirudin as an anticoagulant during cardioplumonary bypass. J Extra Corpor Technol 37:296–302

    Google Scholar 

  55. Jennings DL, Nemerovski CW, Khandelwal A (2010) Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solution. Am J Health Syst Pharm 67(21):1825–1828

    Article  PubMed  Google Scholar 

  56. Crouch MA, Kasiraja V, Cahoon W, Katlaps GJ, Gunnerson KJ (2008) Successful use and dosing of bivalirudin after temporary total artificial heart implanataion: a case series. Pharmacotherapy 28(11):1413–1420

    Article  CAS  PubMed  Google Scholar 

  57. Rihal CS, Naidu SS, Givertz MM et al (2015) 2015 SCAI/ACC/ HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American heart assocation, the cardiological society of India, and Sociedad Latino Americana de Cardiologia intervencion; affirmation of value by the Canadian Association of interventional cardiology association Canadienne de Cardiologie d’intervention. J Am Coll Cardiol 65(19):e7–e26

    Article  PubMed  Google Scholar 

  58. Mousavi S, Levcovich B, Mojtahedzadeh M (2011) A systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation. DARU 19(5):312–321

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Ranucci M, Ballotta A, Kandil H et al (2011) Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 15(6):R275

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kiser TH, MacLaren R, Fish DN, Hassell KL, Teitelbaum I (2010) Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy 30:1117–1126

    Article  CAS  PubMed  Google Scholar 

  61. Pappalardo F, Scandroglio AM, Potapov E, Stepanenko A, Maj G, Krabatsch T, Zangrillo A, Koster A, Hetzer R (2012) Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol 78(3):330–335

    CAS  PubMed  Google Scholar 

  62. Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin JT et al (2004) Effect of direct thrombin-inhibitors: bivalirudin, lepirudin and argatroban, on prothrombin time and INR measurements. Am J Clin Path 121(4):593–599

    Article  CAS  PubMed  Google Scholar 

  63. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA (2007) Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 27(4):564–587

    Article  CAS  PubMed  Google Scholar 

  64. Sullivan DW Jr, Gad SC, Laulicht B (2015) S. Bakhru, S. Steiner Nonclinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 34:308–317

    Article  CAS  PubMed  Google Scholar 

  65. B. Laulicht, S. Bakhru, X. Jiang et al (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. J Thromb Haemost, 11:1322

    Google Scholar 

  66. Van de Werf F, Brueckmann M, Connolly SJ et al (2012) A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). Am Heart J 163:931–937

    Article  PubMed  Google Scholar 

  67. Schmaier AH (2016) Antithrombotic potential of the contact activation pathway. Curr Opin Hematol 23(5):445–452

    Article  CAS  PubMed  Google Scholar 

  68. Weitz JI (2016) Factor XI and factor XII as targets for new anticoagulants. Thromb Res 141(Suppl 2):S40–S45

    Article  CAS  PubMed  Google Scholar 

  69. Koster A WY, Bottcher W, Gromann T (2007) Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg 83:1865–1867

    Article  PubMed  Google Scholar 

  70. Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D (2014) Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol 46(1):94–97

    PubMed  PubMed Central  Google Scholar 

  71. Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD, Zangrillo A, Pappalardo F (2013) Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 27:30–34

    Article  CAS  PubMed  Google Scholar 

  72. Phillips MR, Khoury AL, Ashton RF, Cairns BA, Charles AG (2014) The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care 42(1):97–98

    CAS  PubMed  Google Scholar 

  73. Pappalardo F, Maj G, Scandroglio AM, Sampietro F, Zangrillo A, Koster A (2009) Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion 24(2):135–137

    Article  CAS  PubMed  Google Scholar 

  74. Dolch ME, Frey L, Hatz R, Uberfuhr PA, Beiras-Fernandez A, Behr J, Irlbeck M (2010) Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia. Exp Clin Transplant 8(4):329–332

    PubMed  Google Scholar 

  75. Johnston N, Wait M, Huber L (2007) Argatroban in extracorporeal membrane oxygenation. Artif Organs 31(6):461–465

    Article  Google Scholar 

  76. Parlar AI, Sayar U, Cevirme D, Yuruk MA, Mataraci I (2014) Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery. Int J Artif Organs 37(4):344–347

    Article  PubMed  Google Scholar 

  77. Pieri M AN, Di Prima AL (2014) Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices. Artif Organs 38(4):342–361

    Article  CAS  PubMed  Google Scholar 

  78. Velagic V, Samardzic J, Baricevic Z, Skoric B, Cikes M, Gasparovic H et al (2014) Management of heparin-induced thrombocytopenia with fondaparinux in apatient with left ventricular assist device. Int J Organ Transplant Med 5(2):83

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Samuels LE, Kohout J, Casanova-Ghosh E, Hagan K, Garwood P, Ferinand F et al (2008) Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices. Ann Thorac Surg 85(5):1651–1655

    Article  PubMed  Google Scholar 

  80. Meyer AL, Malehsa D, Kuehn C, Bara C, Gras C, Hafer C, Haverich A, Struber M (2009) HeartMate II implantation in patients with heparin-induced thrombocytopenia type II. Ann Thorac Surg 88:674–675

    Article  PubMed  Google Scholar 

Download references

Funding

This manuscript was not funded.

Author information

Authors and Affiliations

  1. Department of Pharmacy Services, TriStar Centennial Medical Center, Nashville, TN, USA

    Jonathan Bain

  2. Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN, USA

    Jonathan Bain

  3. Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY, USA

    Alexander H. Flannery & Jeremy Flynn

  4. Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA

    Alexander H. Flannery & Jeremy Flynn

  5. University of California-Davis Health System, Sacramento, CA, USA

    William Dager

  6. University of California-San Francisco School of Pharmacy, San Francisco, CA, USA

    William Dager

  7. University of California-Davis School of Medicine, Sacramento, CA, USA

    William Dager

  8. Touro School of Pharmacy, Vallejo, CA, USA

    William Dager

Authors
  1. Jonathan Bain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander H. Flannery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeremy Flynn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William Dager
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Bain.

Ethics declarations

Conflict of interest

Jonathan Bain, Alexander Flannery, Jeremy Flynn, William Dager declares that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human or animal participants performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bain, J., Flannery, A.H., Flynn, J. et al. Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations. J Thromb Thrombolysis 44, 76–87 (2017). https://doi.org/10.1007/s11239-017-1494-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-017-1494-0

Keywords

Search

Navigation